Pharmacokinetics and Safety of VV116 in Subjects With Mild or Moderate Hepatic Impairment Compared With Healthy Controls: A Phase I, Open-Label Study
{{output}}
VV116 (Mindvy, JT001) is a deuterated oral derivative of remdesivir hydrobromide developed for the treatment of COVID-19. Because hepatic dysfunction may influence drug exposure, this Phase 1, open-label, parallel-group study characterized the pharmacokinetics... ...
